NCT02398578终止1 期
Cystoscopic Ablation Via RF Energy Clinical Trial
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 63
- 试验地点
- 4
- 主要终点
- Device-related complications through 24 month follow-up
研究概览
简要总结
Phase I/II study to assess the safety and performance of the Amphora OAB system for treatment of urgency and frequency with or without urge incontinence caused by an overactive bladder.
详细描述
The study will enroll subjects with symptomatic idiopathic overactive bladder (OAB).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Subjects must meet ALL the inclusion criteria to be eligible to participate in the study.
- •Non-pregnant, non-lactating female > 18 years old with a history of idiopathic OAB for ≥ 6 months
- •Have failed or are not a candidate for drug treatment
- •Subject is willing to provide Informed Consent, is geographically stable, understands the requirements for completing the bladder diary and is willing to comply with the required diary, follow up visits and testing schedules
- •Ambulatory without the aid of walking assistance a majority of the time (cane, walker etc.) and able to use toilet without assistance
- •Post-void residual (PVR) ≤ 100 ml NOTE: Subjects with a single PVR of >100 ml followed by two consecutive PVR measurements of ≤100 ml may be included in the study. The final acceptable PVR measurement will be recorded in the data.
- •Ability and willingness to self-catheterize in case this is necessary
- •3 day Bladder Diary Criteria: Symptoms of OAB as evidenced by: Micturition frequency of ≥ 8 times/day And > 3 episodes of urgency urinary incontinence (UUI)
排除标准
- •Subject will be excluded if ANY of the following conditions apply:
- •Planning on becoming pregnant during the 12 month study period
- •Current participation in any other conflicting interventional or OAB treatment study
- •Primary complaint of stress urinary incontinence or stress predominant mixed incontinence or functional incontinence
- •Any invasive or surgical intervention (e.g., radio frequency, implant, sling) involving the bladder, rectum or vaginal wall within the last 6 months
- •Ongoing complications of prior anti-incontinence surgery
- •Subject with 24-hour total urine volume voided greater than 3,000 ml as measured at screening period
- •Receiving electro-stimulation (e.g. PTNS or SNS) treatment within the last 15 days.
- •NOTE: Subjects with an implanted SNS device that has not been active in the last 15 days is acceptable for enrollment
- •Botox treatment for OAB with 100u in the last 6 months OR Botox treatment with >100u in last 9 months
- •Urinary tract infection that is not resolved at the time of enrollment or had > 3 urinary tract infections (UTIs) within the last 12 months NOTE: If UTI is present at baseline screening, treatment with antibiotics and a negative urinalysis at least 7 days after the initial diagnosis of UTI will be acceptable for enrollment.
- •Documented spontaneous unprovoked urinary retention within the last 6 months
- •Anatomical conditions that would preclude the introduction and use of the device, in the opinion of the investigator, such as significant pelvic organ prolapse, urogenital prolapse visible at rest beyond the hymen, significant cystocele prolapse or high BMI
- •Current bleeding disorder or coagulopathies
- •Current use of antimuscarinics, β3 agonist or antispasmodics NOTE: subjects on these drugs must undergo a 2 week washout period prior to completing the baseline Bladder Diary.
- •Subject has been previously diagnosed with interstitial cystitis, bladder cancer or chronic pelvic pain syndrome.
- •Previous pelvic irradiation
- •Serum creatinine > twice the upper limit of normal within the last six months
- •Neurological disease affecting bladder function such as multiple sclerosis, spinal cord injuries, myasthenia gravis, Charcot-Marie-Tooth disease
- •Current hydronephrosis or hydroureter
- •Bladder outflow obstruction
- •Ureteral dysfunction, stricture or reflux
研究组 & 干预措施
Amphora OAB Device
Experimental
Specialized cystoscope that facilitates visualization and radiofrequency (RF) therapy for the treatment of OAB.
干预措施: Amphora OAB Device (Device)
结局指标
主要结局
Device-related complications through 24 month follow-up
时间窗: 24 month
次要结局
- Procedural Success(During the study procedure)
- Change from Baseline of Quality of Life Scores(4 weeks, 12 weeks, 6, 12, 18, and 24 months)
- Device Technical Success(During the study procedure)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
EUS-RFA for Unresectable Pancreatic Ductal AdenocarcinomaPancreatic Adenocarcinoma Non-resectableNCT03772756First People's Hospital of Hangzhou38
进行中（未招募）
不适用
Coherent Sine Burst (CSE) Electroporation System Pilot Study in Patients With Atrial FibrillationAtrial FibrillationNCT05572047Arga Medtech SA25
已完成
不适用
Use of Radiofrequency Ablation for RGB SalvageObesityNCT01910688Medtronic - MITG25
撤回
不适用
Feasibility Study of Ablathermy Focused Ultrasound (USF) of Breast Tumors Before MastectomyBreast TumorNCT01827969Institut Bergonié1
已完成
不适用
Trial to Evaluate the Efficacy and Safety of Substrate Ablation of Monomorphic Ventricular TachycardiaMonomorphic Ventricular TachycardiaNCT03734562Hospital General Universitario Gregorio Marañon180